

Q-linea is offered a loan facility of SEK 100 million from main owner Nexttobe

Q-linea AB (publ) (OMX: QLINEA) today announces that the company's main owner Nexttobe is offering the company SEK 100 million in a loan that can be converted into shares.

Q-linea's terminated distribution collaboration with Thermo Fisher Scientific has not changed the management's and the main owner Nexttobe's view of Q-linea as a long-term successful company in infection diagnostics. Therefore, Nexttobe is offering a loan of SEK 100 million to Q-linea.

The loan is offered without interest, without a time limit and is intended to be converted into shares if the company issues new shares in the future. Any conversion will be made at the current rate at that point.

"I am very happy that our main owner has strong faith in the company and the work we do to improve infection diagnostics. Seeing the development of antibiotic resistance in the world and how diagnostics work for patients with sepsis, and at the same time seeing what ASTar can offer, it is quite clear to me that we have the opportunity of a very strong development for the company. The support from Nexttobe means that we stand strong and can take the next step in our development at our own pace," said Jonas Jarvius, CEO of Q-linea.

"We have always seen Q-linea as a long-term investment with great potential and that has not changed because the collaboration with Thermo Fisher ends. I see that we continue to support the company," said Erika Kjellberg Eriksson, CEO of Nexttobe.

For more information, please contact:

Jonas Jarvius, CEO, Q-linea AB
Jonas.Jarvius@qlinea.com
+46 (0) 70-323 77 60

Anders Lundin, CFO, Q-linea AB
Anders.Lundin@qlinea.com
+46 (0) 70-600 15 20

About Q-linea

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.

Attachments

Q-linea is offered a loan facility of SEK 100 million from main owner Nexttobe